News

Research & Development

May 2017

The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOA) related to nasal delivery of CNS therapeutics. Both FOAs say that their purpose is to “is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).
”The global market for direct-to-CNS-delivery technologies is reported to grow to $450 million by 2019, and has increased by 50% per year since 2013.”

MetP’s platform for nasal delivery of CNS therapeutics is fully developed and ready for commercial-scale production.
Its specific technology (“Silcum®”) essentially includes a symbiosis triangle:

  1. A versatile and stable semi-solid matrix suitable for the molecule chosen. The formulation is safe, virtually odorless and tasteless, and convenient to use. It has shown to deliver molecules to the CNS.
  2. A fingernail-sized single-dose container (“Lecticula®”) with high dosing accuracy (± 3%) and
  3. An appropriate filling machine (“Maxima®”) for the containers


Visit us at Interpack 2017 (May 04-10, 2017 in Duesseldorf/Germany).
MetP is presenting its technology at the “Harro Höfliger” Booth B15 in Hall 16 (www.hoefliger-interpack.com, www.hoefliger.com/unternehmen/netzwerk).

November 2015

Start of clinical Phase IIa trial with MetP’s Progesterone vs. Zolpidem in women suffering from Insomnia Disorder.

October / November 2015

Scheduled start of kinetic studies using the new extended/sustained release formulation for some molecules.

July 2015

MetP Pharma AG starts the development project "Testosterone for women".

March 2015

MetP Pharma AG orders the filling machine and tools for the commercial production of its patented unit-dose container.

February 2015

MetP Pharma AG starts the development work related to its patented extended/sustained release formulation for some molecules of its pipeline.

March/April 2014

MetP Pharma AG inaugurates a new tech center in order to extend R&D for its platform for nasal application and to further improve its service for customers. The following drugs are in progress:

  • Neurosteroids, Neurotransmitter,
  • Anti-dementive drugs (Galantamine; Rivastigmine, Memantine),
  • Glatiramer acetate,
  • Narcotics/drugs for the treatment of severe pain conditions (hydromorphone, oxycodone, buprenorphine, fentanyl.

September 2013

MetP Pharma AG to discuss Feasibility Agreement for Opiate/Analgesic drug development with a Swiss Pharma Company.

August 2013

MetP Pharma AG signs Feasibility Agreement for a Progestin development with a major US-based non-profit organisation

July 2013

MetP Pharma AG renews the Research Agreement regarding Neuroprotection and Neuroregeneration with Inserm Research Unit 788, French National Institute for Health and Medical Research.

July 2013

United States Food and Drug Administration accepts NDA (as filed by MetP’s licensee) for the bioadhesive intranasal gel formulation of testosterone developed by MetP Pharma AG.

2012

MetP Pharma AG completed with positive and encouraging results its first Phase I clinical trial of low-dose, bio-identical intranasal Progesterone (“PRONAS”) for the treatment of sleep dysfunction. In this vehicle-controlled study in postmenopausal women, two doses of PRONAS were compared with the standard dose of Zolpidem (Stilnox®, Sanofi-Aventis), a short-acting non-benzodiazepine hypnotic.

Progesterone is a multifunctional compound; PRONAS is a potentially novel product for the treatment of insomnia characterized by difficulties with sleep initiation. It was developed with the aim of providing a smooth mode of action, also reducing the risk of overuse, addiction and hangover.

MetP Pharma AG completed its phase I pharmacokinetic study (PK), assessing safety and PK of 3 doses of “NOSEAFIX” (low-dose, bio-identical testosterone, applied intranasally). The results showed good bioavailability for the intranasal formulation and a safe kinetic profile. No serious events or unexpected side effects were experienced during the study.

MetP Pharma AG completed with positive and encouraging results its first Phase II clinical trial of NOSEAFIX for the treatment of Hypoactive Sexual Desire Disorder (HSDD). In this vehicle-controlled electro-physiological study with visual erotic stimulation, non-erotic emotional stimulation and relaxing segments, 2 doses of NOSEAFIX were compared. Assessments included subjective sexual arousal, electro-encephalographic signals, electro-cardiogram and electro-dermal response, as well as a correlation to testosterone levels.

Testosterone is a multifunctional compound; NOSEAFIX is a potentially novel product for the treatment or adjuvant therapy of women suffering from low levels of testosterone (e.g. in Turner’s syndrome, mild depression, bone loss, frailty, hot flashes). It has also shown to be useful in HSDD, characterized by a lack or absence of sexual fantasies and desire for sexual activity.
NOSEAFIX was developed with the aim of providing a smooth mode of action; it is fast but long-acting and thus can be taken on demand.